Dexrazoxane Hydrochloride – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 83 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page10 sections

Article Summary

Dexrazoxane Hydrochloride is the hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. Dexrazoxane is a...

Key Takeaways

This article explains Mechanism of Action in simple medical language.
This article explains Indications in simple medical language.
This article explains Contraindications in simple medical language.
This article explains Dosage in simple medical language.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Evidence Trust Passport

How this article is supported

79/100

Written byDr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Medical review1 reviewer

Last reviewedNot scheduled

Next reviewNot scheduled

References1 source entry

Review statusReview schedule needed

Medical library classification Drug monograph Drugs A–Z

This passport makes the article’s review, evidence, and update signals visible. It does not guarantee that every section is complete or replace personal medical advice.

Definition

Dexrazoxane Hydrochloride is the hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.

Dexrazoxane is a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.

Dexrazoxane is a cytoprotective drug used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer. An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit the formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.

Mechanism of Action

The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protected through its inhibitory effect on topoisomerase II.

The mechanism of action of dexrazoxane’s cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of ethylenediamine tetra-acetic acid (EDTA) that readily penetrates cell membranes. Laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.

Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. Patients receiving anthracycline-derivative antineoplastic agents may experience three types of cardiotoxicity: acute transient type; chronic, subacute type (related to cumulative dose and has a more indolent onset later on); and a late-onset type that manifests years after therapy, mainly in patients that have been exposed to the drug as a child. Although the exact mechanism of anthracycline-induced cardiotoxicity is not known, it has been shown to exert a variety of actions that may result in the development of cardiotoxicity. In animals, anthracyclines cause a selective inhibition of cardiac muscle gene expression for α-actin, troponin, myosin light-chain 2, and the M isoform of creatine kinase. This may lead to myofibrillar loss associated with anthracycline-induced cardiotoxicity. Anthracyclines may also cause myocyte damage via calcium overload, altered myocardial adrenergic function, the release of vasoactive amines, and proinflammatory cytokines. Furthermore, it has been suggested that the main cause of anthracycline-induced cardiotoxicity is associated with free-radical damage to DNA. The drugs intercalate DNA, chelate metal ions to produce drug-metal complexes, and generate superoxide radicals via oxidation-reduction reactions. Anthracyclines also contain a quinone structure that can undergo reduction via NADPH-dependent reactions to produce a semiquinone free radical that initiates a cascade of superoxide and hydroxide radical generation. Chelation of metal ions, particularly iron, by anthracyclines results in an anthracycline-metal complex that catalyzes the generation of reactive oxygen free radicals. This complex is a powerful oxidant that can initiate lipid peroxidation in the absence of oxygen free radicals. The toxicity induced by anthracyclines may be exacerbated in cardiac cells, as these cells do not possess sufficient amounts of certain enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) involved in detoxifying free radicals and protecting the cells from subsequent damage.

Indications

For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
Save is indicated for the treatment of anthracycline extravasation.
Dexrazoxane is indicated for reducing the incidence and severity of cardiomyopathy associated with the administration of doxorubicin in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/sq m of the body surface and who would benefit from continued therapy with doxorubicin.
Accidental extravasation of chemotherapy containing anthracycline often causes mutilating complications as a result of extensive tissue necrosis. Treatment, therefore, consists of extensive surgical debridement.
Reducing incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin.

FDA-approved indications:

Reduction of incidence and severity of cardiac dysfunction associated with anthracycline use.
Dexrazoxane can also be used to treat tissue damage caused by anthracyclines when they leak from the vein while being administered.

Non-FDA-approved indication:

Although a study is still underway as of this writing, dexrazoxane may act as a beneficial neuroprotectant to treat neurodegeneration in patients with Parkinson’s disease.[rx]

Use in Cancer

Dexrazoxane hydrochloride is approved to treat severe side effects caused by certain types of chemotherapy. It is used to treat the following:

Cardiac (heart) side effects caused by doxorubicin hydrochloride in women being treated for metastatic breast cancer. Dexrazoxane hydrochloride helps make the side effects happen less often and makes them less severe when they do occur. It is used only in women who have already received high doses of doxorubicin and continue to be treated with it. This use is approved for the Totect and Zinecard brands of dexrazoxane hydrochloride.
Extravasation caused by intravenous anthracyclines. Extravasation occurs when injected drugs leak out of the vein, into the surrounding tissue. This can cause redness, pain, and swelling, and may damage the tissue. This use is approved for the Totect brand of dexrazoxane hydrochloride.

Contraindications

decreased blood platelets
low levels of white blood cells
low levels of a type of white blood cell called neutrophils
pregnancy
a patient who is producing milk and breastfeeding
chronic kidney disease stage 3B (moderate)
chronic kidney disease stage 4 (severe)
chronic kidney disease stage 5 (failure)
kidney disease with likely reduction in kidney function

Dosage

Strengths: 250 mg; 500 mg

Cardiomyopathy Prophylaxis

The dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g. 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin)

Administer via IV infusion over 15 minutes.
DO NOT administer via IV push.
Administer doxorubicin within 30 minutes of completion of dexrazoxane infusion; do not administer doxorubicin before dexrazoxane.
Do not use it with the initiation of doxorubicin therapy.

Extravasation

Recommended doses:

Day one: 1000 mg/m2 IV over 1 to 2 hours
Day two: 1000 mg/m2 IV over 1 to 2 hours
Day three: 500 mg/m2 IV over 1 to 2 hours

Maximum doses:

Day one: 2000 mg
Day two: 2000 mg
Day three: 1000 mg
The product must be diluted with 50 mL of 0.167 M sodium lactate injection solution prior to administration.
Initiate the first infusion as soon as possible and within the first 6 hours of extravasation.
Start day 2 and 3 treatments at the same hour as the first day (give or take 3 hours).
Remove cooling features such as ice packs (if used) at least 15 minutes before administration to allow sufficient blood flow to the extravasation area.

Side Effects

The Most Common

pain or swelling in the place where the medication was injected
nausea
vomiting
diarrhea
constipation
stomach pain
loss of appetite
dizziness
headache
excessive tiredness
difficulty falling asleep or staying asleep
depression
swelling of the arms, hands, feet, ankles, or lower legs
sore throat, fever, chills, cough, and other signs of infection
unusual bruising or bleeding
pale skin
weakness
shortness of breath
rash
itching
hives
difficulty breathing or swallowing
swelling of the eyes, face, mouth, lips, tongue, or throat
dizziness
fainting

More common

Blurred or double vision
diarrhea
difficulty having a bowel movement
difficulty in swallowing
difficulty in walking
discouragement
dizziness
drooping eyelids
fainting
feeling sad or empty
hair loss
headache
heartburn
irritability
jaw pain
lack or loss of appetite
lightheadedness
loss of interest or pleasure
muscle pain, spasms, cramps, or stiffness
nausea
numbness or tingling in the fingers and toes
pain in the fingers and toes
pain in the testicles
pain or burning in the throat
pain or redness at the site of injection
pale skin at the site of injection
rapid, shallow breathing
stomach pain
swelling or inflammation of the mouth
thinning of the hair
trouble concentrating
trouble sleeping
vomiting
weight loss

Rare

Bluish color
changes in skin color
chest pain or tightness
chills
cold hands and feet
cough
fever
hoarseness
lower back or side pain
pain, redness, or swelling in the arm or leg
painful or difficult urination
pale skin
sneezing
sore throat
swelling of the hands, ankles, feet, or lower legs
tenderness
trouble breathing
unusual bleeding or bruising
unusual tiredness or weakness
Black, tarry stools
chest discomfort
fast, irregular, or pounding heartbeat
pain at the injection site
ulcers, sores, or white spots in the mouth

Drug Interactions

DRUG	INTERACTION
Abacavir	Dexrazoxane may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abatacept	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Dexrazoxane.
Aceclofenac	Aceclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Acenocoumarol	The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dexrazoxane.
Acetaminophen	Acetaminophen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dexrazoxane.
Aclidinium	Dexrazoxane may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Dexrazoxane may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Dexrazoxane.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Adenovirus	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Dexrazoxane.
Albutrepenonacog	Dexrazoxane may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexrazoxane.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Dexrazoxane.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexrazoxane.
Allogeneic	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Dexrazoxane.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Dexrazoxane.
Almasilate	Dexrazoxane may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Dexrazoxane may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Alogliptin	Dexrazoxane may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Alprazolam	Dexrazoxane may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Dexrazoxane.
Altretamine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Altretamine.
Amantadine	Dexrazoxane may decrease the excretion rate of Amantadine which could result in a higher serum level.
Amikacin	Dexrazoxane may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone	Aminophenazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Amitriptyline	Amitriptyline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ammonium chloride	Dexrazoxane may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amoxicillin	Dexrazoxane may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine	Amphetamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Amphotericin B	Amphotericin B may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ampicillin	Dexrazoxane may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Amrinone	Dexrazoxane may decrease the excretion rate of Amrinone which could result in a higher serum level.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Dexrazoxane.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Dexrazoxane.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Dexrazoxane.
Ancestim	Dexrazoxane may decrease the excretion rate of Ancestim which could result in a higher serum level.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Dexrazoxane.
Anifrolumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Dexrazoxane.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dexrazoxane.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Dexrazoxane.
Antihemophilic	Dexrazoxane may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
antilymphocyte	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	Antipyrine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dexrazoxane.
Antithrombin III human	Dexrazoxane may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexrazoxane.
Antrafenine	Antrafenine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Apalutamide	Dexrazoxane may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Apixaban	The risk or severity of bleeding can be increased when Apixaban is combined with Dexrazoxane.
Apremilast	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Apremilast.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Dexrazoxane.
Arformoterol	Dexrazoxane may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Dexrazoxane.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Arsenic trioxide.
COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane.
Atazanavir	Atazanavir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Atomoxetine	Atomoxetine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Auranofin	Dexrazoxane may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose	Dexrazoxane may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Azacitidine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Azacitidine.
Azathioprine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Azathioprine.
Azelaic acid	Dexrazoxane may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Aztreonam	Aztreonam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Bacillus antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Dexrazoxane.
Bacillus calmette	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Dexrazoxane.
Bacillus antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Dexrazoxane.
Bacitracin	Bacitracin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Baclofen	Baclofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Balsalazide	Balsalazide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Baricitinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexrazoxane.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Dexrazoxane.
Beclomethasone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Beclomethasone dipropionate.
Belatacept	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Dexrazoxane.
Bendamustine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bendamustine.
Bendroflumethiazide	Bendroflumethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Benorilate	Benorilate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Benserazide	Dexrazoxane may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	Benzatropine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Benznidazole	Dexrazoxane may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzthiazide	Benzthiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Bepotastine	Dexrazoxane may decrease the excretion rate of Bepotastine which could result in a higher serum level.
Betamethasone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Betamethasone.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Dexrazoxane.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexrazoxane.
Bicisate	Dexrazoxane may decrease the excretion rate of Bicisate which could result in a higher serum level.

Bimekizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bimekizumab.
Bismuth subgallate	Dexrazoxane may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bisoprolol	Dexrazoxane may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
Bisoxatin	Dexrazoxane may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Dexrazoxane.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexrazoxane.
Blinatumomab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Blinatumomab.
Bordetella	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Dexrazoxane.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexrazoxane.
Bosutinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bosutinib.
Brentuximab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brentuximab vedotin.
Brivaracetam	Dexrazoxane may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Brodalumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brodalumab.
Bromazepam	Dexrazoxane may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Budesonide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Budesonide.
Bumadizone	Bumadizone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Bumetanide	Bumetanide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Bupropion	Dexrazoxane may decrease the excretion rate of Bupropion which could result in a higher serum level.
Buspirone	Dexrazoxane may decrease the excretion rate of Buspirone which could result in a higher serum level.
Busulfan	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Busulfan.
Butabarbital	Butabarbital may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cabazitaxel	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cabazitaxel.
Canagliflozin	Canagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Canakinumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Dexrazoxane.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dexrazoxane.
Capreomycin	Dexrazoxane may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Carbamazepine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carbamazepine.
Carbidopa	Carbidopa may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Carboplatin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carboplatin.
Carfilzomib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Dexrazoxane.
Carprofen	Carprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefaclor	Cefaclor may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefdinir	Dexrazoxane may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ceftolozane	Dexrazoxane may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cephalexin	Cephalexin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Certolizumab pegol.
Cetirizine	Cetirizine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cevimeline	Cevimeline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Chloral hydrate	Dexrazoxane may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dexrazoxane.
Chloramphenicol	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Chloramphenicol.
Chloroquine	Dexrazoxane may decrease the excretion rate of Chloroquine which could result in a higher serum level.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Chloroxylenol	Dexrazoxane may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Chlorpromazine	Dexrazoxane may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.
Chlorpropamide	Dexrazoxane may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	Chlorzoxazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Choline C 11	Dexrazoxane may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Choline magnesium	Choline magnesium trisalicylate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Choline salicylate	Dexrazoxane may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate	Dexrazoxane may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Dexrazoxane may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Dexrazoxane may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Dexrazoxane may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Dexrazoxane may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate	Dexrazoxane may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Dexrazoxane may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Ciclesonide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ciclesonide.
Cidofovir	Cidofovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Cilostazol	The risk or severity of bleeding can be increased when Cilostazol is combined with Dexrazoxane.
Cimetidine	Dexrazoxane may decrease the excretion rate of Cimetidine which could result in a higher serum level.
Ciprofloxacin	Dexrazoxane may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
Cisplatin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Dexrazoxane.

Clevidipine	Dexrazoxane may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Clobazam	Clobazam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Clobetasol propionate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clofarabine.
Clomipramine	Dexrazoxane may decrease the excretion rate of Clomipramine which could result in a higher serum level.
Clonazepam	Dexrazoxane may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Clopidogrel	The risk or severity of bleeding can be increased when Clopidogrel is combined with Dexrazoxane.
Clorazepic acid	Dexrazoxane may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane.
Clove oil	Dexrazoxane may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	The risk or severity of neutropenia can be increased when Dexrazoxane is combined with Clozapine.
Colchicine	Dexrazoxane may decrease the excretion rate of Colchicine which could result in a higher serum level.
Colistimethate	Colistimethate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Colistin	Dexrazoxane may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	Conivaptan may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Conjugated estrogens	Conjugated estrogens may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Corifollitropin alfa	Dexrazoxane may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Corticotropin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Corticotropin.
Cortisone acetate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dexrazoxane.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cyclophosphamide.
Cyclosporine	Dexrazoxane may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Cytarabine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Dexrazoxane.
Dabigatran etexilate	Dexrazoxane may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Dacarbazine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dacarbazine.
Dactinomycin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dactinomycin.
Dalfampridine	Dexrazoxane may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Dexrazoxane.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Dexrazoxane.
Dapagliflozin	Dapagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Daptomycin	Daptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Dasatinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dasatinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Decitabine.
Deferiprone	Dexrazoxane may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Dexrazoxane.
Deflazacort	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Deflazacort.
Delafloxacin	Dexrazoxane may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Dexrazoxane.
Desipramine	Dexrazoxane may decrease the excretion rate of Desipramine which could result in a higher serum level.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Dexrazoxane.
Desmopressin	Desmopressin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Desoximetasone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Desoximetasone.
Desvenlafaxine	Dexrazoxane may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Deucravacitinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Deucravacitinib.
Deutetrabenazine	Dexrazoxane may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dexamethasone.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Dexmedetomidine	Dexrazoxane may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Dexpanthenol	Dexrazoxane may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dextran	Dexrazoxane may decrease the excretion rate of Dextran which could result in a higher serum level.
Diatrizoate	Diatrizoate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Diazepam	Dexrazoxane may decrease the excretion rate of Diazepam which could result in a higher serum level.
Dichlorobenzyl	Dexrazoxane may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	Diclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Diclofenamide	Diclofenamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Dexrazoxane.
Dicyclomine	Dexrazoxane may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Didanosine	Dexrazoxane may decrease the excretion rate of Didanosine which could result in a higher serum level.
Dienogest	Dexrazoxane may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diflunisal	Diflunisal may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Difluocortolone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Difluocortolone.
Digoxin	Dexrazoxane may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Dimercaprol	Dexrazoxane may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dimethyl fumarate.
Dimethyl sulfoxide	The therapeutic efficacy of Dexrazoxane can be decreased when used in combination with Dimethyl sulfoxide.
Dinutuximab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dinutuximab.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Dexrazoxane.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Diroximel fumarate.
Disopyramide	Disopyramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DMethylephedrine	Dexrazoxane may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Dexrazoxane may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Docetaxel	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Docetaxel.
Dopamine	Dexrazoxane may decrease the excretion rate of Dopamine which could result in a higher serum level.
Doripenem	Dexrazoxane may decrease the excretion rate of Doripenem which could result in a higher serum level.
Doxacurium	Dexrazoxane may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Doxepin	Dexrazoxane may decrease the excretion rate of Doxepin which could result in a higher serum level.
Doxorubicin	The therapeutic efficacy of Doxorubicin can be decreased when used in combination with Dexrazoxane.
Doxycycline	Doxycycline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Drospirenone	Drospirenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dexrazoxane.
Droxidopa	Dexrazoxane may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Duloxetine	Dexrazoxane may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Dyphylline	Dexrazoxane may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Ebola Zaire]	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Dexrazoxane.
Eculizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Dexrazoxane.
Edoxaban	Dexrazoxane may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Dexrazoxane may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexrazoxane.
Emapalumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Emapalumab.
Enalaprilat	Dexrazoxane may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Dexrazoxane.
Enzalutamide	Dexrazoxane may decrease the excretion rate of Enzalutamide which could result in a higher serum level.

Epirubicin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Epirubicin.
Eplerenone	Eplerenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Dexrazoxane.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Dexrazoxane.
Eribulin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Eribulin.
Ertapenem	Ertapenem may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ertugliflozin	Ertugliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Estazolam	Dexrazoxane may decrease the excretion rate of Estazolam which could result in a higher serum level.
Estradiol	Dexrazoxane may decrease the excretion rate of Estradiol which could result in a higher serum level.
Estradiol acetate	Dexrazoxane may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate	Dexrazoxane may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate	Dexrazoxane may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate	Dexrazoxane may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Estramustine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Estramustine.
Estrone sulfate	Dexrazoxane may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Eszopiclone	Dexrazoxane may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Dexrazoxane may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Dexrazoxane.
Ethambutol	Ethambutol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Etodolac	Etodolac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Etomidate	Etomidate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Etonogestrel	Etonogestrel may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Etoposide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Etoposide.
Etoricoxib	Etoricoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Eucalyptus oil	Dexrazoxane may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Everolimus	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Everolimus.
Ezogabine	Dexrazoxane may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Dexrazoxane.
Fenbufen	Fenbufen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Fenofibrate	Dexrazoxane may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Fenofibric acid	Dexrazoxane may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	Dexrazoxane may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Fentanyl	Dexrazoxane may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Fesoterodine	Dexrazoxane may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Filgotinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Filgotinib.
Finerenone	Finerenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Fingolimod	Dexrazoxane may increase the immunosuppressive activities of Fingolimod.
Flavoxate	Dexrazoxane may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Floctafenine	Floctafenine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Florbetaben (18F)	Dexrazoxane may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F)	Dexrazoxane may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Dexrazoxane.
Fluconazole	Fluconazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Flucytosine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludarabine.
Fludeoxyglucose	Dexrazoxane may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fludrocortisone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludrocortisone.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Dexrazoxane.
Flumazenil	Dexrazoxane may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Dexrazoxane.
Fluocinolone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinolone acetonide.
Fluocinonide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinonide.
Fluocortolone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Dexrazoxane.
Fluorouracil	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluorouracil.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dexrazoxane.
Fluprednisolone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluprednisolone.
Flurazepam	Dexrazoxane may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Flutamide	Dexrazoxane may decrease the excretion rate of Flutamide which could result in a higher serum level.
Fluticasone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone furoate.
Fluticasone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone propionate.
Fluvoxamine	Fluvoxamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Folic acid	Folic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Fomepizole	Dexrazoxane may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fondaparinux	Dexrazoxane may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Formestane	Dexrazoxane may decrease the excretion rate of Formestane which could result in a higher serum level.
Foscarnet	Foscarnet may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Fosfomycin	Dexrazoxane may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Fosinopril	Dexrazoxane may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Framycetin	Framycetin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Furosemide	Furosemide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Gabapentin enacarbil	Dexrazoxane may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	Dexrazoxane may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Gadofosveset	Dexrazoxane may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Dexrazoxane may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Gadoteric acid	Dexrazoxane may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Dexrazoxane may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Gallium nitrate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Gallium nitrate.
Ganciclovir	Dexrazoxane may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Gemcitabine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Gemcitabine.
Gemfibrozil	Dexrazoxane may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
Gemtuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane.
Gentamicin	Dexrazoxane may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gimeracil	Dexrazoxane may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	Givosiran may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Glatiramer	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Glatiramer.
Glipizide	Dexrazoxane may decrease the excretion rate of Glipizide which could result in a higher serum level.
Glycerol	Dexrazoxane may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Golimumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Golimumab.
Golodirsen	Dexrazoxane may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Guanethidine	Dexrazoxane may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Guanfacine	Dexrazoxane may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Guselkumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Guselkumab.

Hydralazine	Dexrazoxane may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Hydrochlorothiazide	Hydrochlorothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Hydrocortisone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone acetate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone butyrate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone succinate.
Hydroflumethiazide	Hydroflumethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone	Hydromorphone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Hydroxocobalamin	Hydroxocobalamin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydroxychloroquine.
Hydroxyethyl Starch	Dexrazoxane may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyurea	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydroxyurea.
Ibritumomab	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane.
Ibrutinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ibrutinib.
Ibuprofen	Ibuprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ibutilide	Ibutilide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Icatibant	Dexrazoxane may decrease the excretion rate of Icatibant which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dexrazoxane.
Idarubicin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idarubicin.
Idarucizumab	Dexrazoxane may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Dexrazoxane may decrease the excretion rate of Idebenone which could result in a higher serum level.
Idelalisib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idelalisib.
Ifosfamide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ifosfamide.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Dexrazoxane.
Imatinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Imatinib.
Imipramine	Dexrazoxane may decrease the excretion rate of Imipramine which could result in a higher serum level.
Indapamide	Indapamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Indigotindisulf	Dexrazoxane may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexrazoxane.
Inebilizumab	The risk or severity of infection can be increased when Dexrazoxane is combined with Inebilizumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Dexrazoxane.

othalamic acid	Dexrazoxane may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol	Dexrazoxane may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan	Dexrazoxane may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Ipecac	Dexrazoxane may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab	Dexrazoxane may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Irinotecan	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Irinotecan.
Isoniazid	Dexrazoxane may decrease the excretion rate of Isoniazid which could result in a higher serum level.
Isosorbide	Isosorbide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide	Dexrazoxane may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Isosulfan blue	Dexrazoxane may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin	Dexrazoxane may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Isoxicam	Isoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Isradipine	Isradipine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ixabepilone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ixabepilone.
Ixazomib	Dexrazoxane may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ixekizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ixekizumab.
COVID Vaccine	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane.
Japanese encephalitis	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane.
Kanamycin	Dexrazoxane may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	Dexrazoxane may decrease the excretion rate of Ketamine which could result in a higher serum level.
Ketazolam	Dexrazoxane may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Ketoprofen	Ketoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Labetalol	Dexrazoxane may decrease the excretion rate of Labetalol which could result in a higher serum level.
Lamivudine	Dexrazoxane may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Lamotrigine	Dexrazoxane may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
Latamoxef	Latamoxef may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ledipasvir	Dexrazoxane may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Leflunomide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Lenalidomide.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane.
Lesinurad	Dexrazoxane may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Leuprolide	Leuprolide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Levobupivacaine	Dexrazoxane may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
Levocarnitine	Dexrazoxane may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Levocetirizine	Dexrazoxane may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Levofloxacin	Dexrazoxane may decrease the excretion rate of Levofloxacin which could result in a higher serum level.

Levosalbutamol	Dexrazoxane may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Linezolid	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Linezolid.
Liothyronine	Liothyronine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Lipegfilgrastim	Dexrazoxane may increase the myelosuppressive activities of Lipegfilgrastim.
Lisinopril	Dexrazoxane may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Lithium carbonate	Dexrazoxane may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lithium citrate	Lithium citrate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Lixisenatide	Dexrazoxane may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Lofexidine	Dexrazoxane may decrease the excretion rate of Lofexidine which could result in a higher serum level.
Lomustine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Lomustine.
Lopinavir	The serum concentration of Dexrazoxane can be increased when it is combined with Lopinavir.
Loracarbef	Loracarbef may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Lorazepam	Lorazepam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Lorcaserin	Dexrazoxane may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
Lornoxicam	Lornoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Lorpiprazole	Dexrazoxane may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Loxoprofen	Loxoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Lubiprostone	Dexrazoxane may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Lumiracoxib	Lumiracoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Macitentan	Dexrazoxane may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Dexrazoxane.
Magnesium carbonate	Dexrazoxane may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chloride	Dexrazoxane may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium	Dexrazoxane may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium	Dexrazoxane may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mangafodipir	Dexrazoxane may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Mannitol	Mannitol may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Maprotiline	Dexrazoxane may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Measles virus	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Dexrazoxane.
Mecamylamine	Dexrazoxane may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Mechlorethamine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mechlorethamine.
Meclofenamic acid	Meclofenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Medroxyprogesterone	Dexrazoxane may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
Mefenamic acid	Mefenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Megestrol acetate	Megestrol acetate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Meloxicam	Meloxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Melphalan	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Melphalan.
Memantine	Dexrazoxane may decrease the excretion rate of Memantine which could result in a higher serum level.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Dexrazoxane.
Meperidine	Dexrazoxane may decrease the excretion rate of Meperidine which could result in a higher serum level.
Mepivacaine	Dexrazoxane may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
Mepolizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mepolizumab.
Meprednisone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mercaptopurine.
Meropenem	Dexrazoxane may decrease the excretion rate of Meropenem which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Metamfetamine	Dexrazoxane may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Metaxalone	Dexrazoxane may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Metformin	Metformin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Methadone	Methadone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Methazolamide	Methazolamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methotrexate.
Methoxsalen	Dexrazoxane may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Methyldopa	Dexrazoxane may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Methylene blue	Dexrazoxane may decrease the excretion rate of Methylene blue which could result in a higher serum level.
Methylnaltrexone	Dexrazoxane may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methylprednisolone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methylprednisolone.
Methyltestosterone	Dexrazoxane may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Meticrane	Meticrane may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	Dexrazoxane may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Metolazone	Metolazone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Metoprolol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Metyrapone	Dexrazoxane may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Midazolam	Dexrazoxane may decrease the excretion rate of Midazolam which could result in a higher serum level.
Migalastat	Dexrazoxane may decrease the excretion rate of Migalastat which could result in a higher serum level.
Milnacipran	Dexrazoxane may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Milrinone	Milrinone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Mirabegron	Dexrazoxane may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Dexrazoxane.
Mitoxantrone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mitoxantrone.
COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane.
Modified vaccinia	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Dexrazoxane.
Mometasone furoate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mometasone furoate.
Monomethyl fumarate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Monomethyl fumarate.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mosunetuzumab.
Moxisylyte	Dexrazoxane may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Mumps virus	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Dexrazoxane.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Dexrazoxane.
Muzolimine	Muzolimine may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mycophenolate mofetil.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mycophenolic acid.
N-acetyltyrosine	Dexrazoxane may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabumetone	Nabumetone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Nadolol	Dexrazoxane may decrease the excretion rate of Nadolol which could result in a higher serum level.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Dexrazoxane.
Naldemedine	Dexrazoxane may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene	Dexrazoxane may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Naloxone	Dexrazoxane may decrease the excretion rate of Naloxone which could result in a higher serum level.
Naproxen	Naproxen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Natalizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Natalizumab.
Nateglinide	Dexrazoxane may decrease the excretion rate of Nateglinide which could result in a higher serum level.
Nedaplatin	Dexrazoxane may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Dexrazoxane may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Nefazodone	Dexrazoxane may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Nelarabine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Nelarabine.
Neomycin	Dexrazoxane may decrease the excretion rate of Neomycin which could result in a higher serum level.
Netilmicin	Dexrazoxane may decrease the excretion rate of Netilmicin which could result in a higher serum level.

Nicorandil	Dexrazoxane may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Nifedipine	Dexrazoxane may decrease the excretion rate of Nifedipine which could result in a higher serum level.
Nilotinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Nilotinib.
Nilutamide	Dexrazoxane may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Dexrazoxane.
Nisoldipine	Dexrazoxane may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Nitric Oxide	Dexrazoxane may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Nitrofurantoin	Dexrazoxane may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Nitroprusside	Nitroprusside may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Dexrazoxane.
Obinutuzumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Dexrazoxane.
Octinoxate	Dexrazoxane may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Ofatumumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ofatumumab.
Olaparib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Olaparib.
Olsalazine	Olsalazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Opium	Dexrazoxane may decrease the excretion rate of Opium which could result in a higher serum level.
Oseltamivir	Oseltamivir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Oxacillin	Dexrazoxane may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Oxaliplatin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Oxaliplatin.
Oxaprozin	Oxaprozin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Oxazepam	Dexrazoxane may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Oxybenzone	Dexrazoxane may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Oxyquinoline	Dexrazoxane may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Ozanimod	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Paclitaxel.
Palbociclib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Dexrazoxane.
Paliperidone	Dexrazoxane may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Palonosetron	Palonosetron may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Panobinostat	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Panobinostat.
Pantoprazole	Pantoprazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Parecoxib	Parecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Dexrazoxane.
Paromomycin	Paromomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Patent Blue	Dexrazoxane may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pazopanib.
Pegaptanib	Dexrazoxane may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexrazoxane.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pegcetacoplan.
Peginesatide	Dexrazoxane may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexrazoxane.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexrazoxane.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pemetrexed.
Penbutolol	Dexrazoxane may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Penicillamine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Penicillamine.
Pentaerythritol	Dexrazoxane may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Pentamidine	Pentamidine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Pentastarch	Dexrazoxane may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Dexrazoxane may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	Pentobarbital may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Dexrazoxane.
Pentostatin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pentostatin.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Dexrazoxane.
Perindopril	Dexrazoxane may decrease the excretion rate of Perindopril which could result in a higher serum level.
Permethrin	Dexrazoxane may decrease the excretion rate of Permethrin which could result in a higher serum level.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Dexrazoxane.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Phenelzine	Dexrazoxane may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Dexrazoxane.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Dexrazoxane.
Phentolamine	Dexrazoxane may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexrazoxane.
Phenylbutazone	Phenylbutazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Pholcodine	Dexrazoxane may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Dexrazoxane may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Dexrazoxane may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Picosulfuric acid	Dexrazoxane may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexrazoxane.
Pindolol	Dexrazoxane may decrease the excretion rate of Pindolol which could result in a higher serum level.
Piperacillin	Piperacillin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Piracetam	Dexrazoxane may decrease the excretion rate of Piracetam which could result in a higher serum level.
Piretanide	Piretanide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Pirfenidone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pirfenidone.
Piroxicam	Piroxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Pitolisant	Dexrazoxane may decrease the excretion rate of Pitolisant which could result in a higher serum level.
Plazomicin	Dexrazoxane may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Dexrazoxane may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Polythiazide	Polythiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ponatinib.
Ponesimod	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ponesimod.
Potassium	Potassium may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Dexrazoxane may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate	Dexrazoxane may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Potassium cation may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Potassium	Dexrazoxane may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Potassium citrate	Potassium citrate may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate	Dexrazoxane may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium	Dexrazoxane may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Potassium sulfate	Dexrazoxane may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralatrexate	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pralatrexate.
Pralidoxime	Dexrazoxane may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Pramipexole	Dexrazoxane may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Dexrazoxane.
Prednisolone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisolone.
Prednisone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisone.

Pregabalin	Pregabalin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Probenecid	Dexrazoxane may decrease the excretion rate of Probenecid which could result in a higher serum level.
Procainamide	Dexrazoxane may decrease the excretion rate of Procainamide which could result in a higher serum level.
Procaine	Dexrazoxane may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Procarbazine.
Promethazine	Dexrazoxane may decrease the excretion rate of Promethazine which could result in a higher serum level.
Propantheline	Dexrazoxane may decrease the excretion rate of Propantheline which could result in a higher serum level.
Propiverine	Dexrazoxane may decrease the excretion rate of Propiverine which could result in a higher serum level.
Propranolol	Dexrazoxane may decrease the excretion rate of Propranolol which could result in a higher serum level.
Propylthiouracil	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Propylthiouracil.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Dexrazoxane.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Dexrazoxane.
Prucalopride	Dexrazoxane may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Pyrantel	Dexrazoxane may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Pyrazinamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Pyridoxine	Pyridoxine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Pyrithione	Dexrazoxane may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Quetiapine	Dexrazoxane may decrease the excretion rate of Quetiapine which could result in a higher serum level.
Quinethazone	Quinethazone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	Dexrazoxane may decrease the excretion rate of Quinidine which could result in a higher serum level.
Rabeprazole	Dexrazoxane may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Rabies immune	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Dexrazoxane.
Rabies antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dexrazoxane.
Rabies antigen, B	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Dexrazoxane.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dexrazoxane.
Ramelteon	Dexrazoxane may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Ranitidine	Dexrazoxane may decrease the excretion rate of Ranitidine which could result in a higher serum level.
Ranolazine	Ranolazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Rasagiline	Dexrazoxane may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Ravulizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ravulizumab.
Reserpine	Reserpine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Resorcinol	Dexrazoxane may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Dexrazoxane.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Dexrazoxane.
Ribavirin	Dexrazoxane may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Ribostamycin	Dexrazoxane may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rilonacept	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Rilonacept.
Risankizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Risankizumab.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Dexrazoxane.
Rivaroxaban	Dexrazoxane may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rizatriptan	Dexrazoxane may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Rofecoxib	Rofecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Dexrazoxane.
Ropeginterferon	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ropeginterferon alfa-2b.
Ropivacaine	Ropivacaine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Rosiglitazone	Dexrazoxane may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Dexrazoxane.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Dexrazoxane.
Ruxolitinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ruxolitinib.
Sacubitril	Dexrazoxane may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salbutamol	Dexrazoxane may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Salicylamide	Salicylamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Salicylic acid	Salicylic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Salmon calcitonin	Salmon calcitonin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Sarilumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Satralizumab.
Saxagliptin	Dexrazoxane may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Secobarbital	Dexrazoxane may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Secukinumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Secukinumab.
Selenious acid	Dexrazoxane may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Dexrazoxane may decrease the excretion rate of Selenium which could result in a higher serum level.
Sibutramine	Dexrazoxane may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Siltuximab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Siltuximab.
Siponimod	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexrazoxane.
Sirolimus	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sirolimus.
Sitagliptin	Dexrazoxane may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
SVaccine, Live	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Dexrazoxane.
Sodium acetate	Dexrazoxane may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium	Dexrazoxane may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Dexrazoxane.
Sodium fluoride	Dexrazoxane may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate	Dexrazoxane may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir	Dexrazoxane may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solriamfetol	Dexrazoxane may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Sorafenib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sorafenib.
Sorbitol	Dexrazoxane may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Spesolimab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Spesolimab.
Spironolactone	Spironolactone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Stiripentol	Dexrazoxane may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Dexrazoxane.
Streptomycin	Dexrazoxane may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Streptozocin.
Strontium chloride	Dexrazoxane may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Sucralfate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Sulbactam	Dexrazoxane may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	Sulfadiazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dexrazoxane.
Sulfasalazine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sulfasalazine.
Sulfinpyrazone	The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dexrazoxane.
Sulindac	Sulindac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Dexrazoxane.
Sumatriptan	Dexrazoxane may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Sunitinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sunitinib.
S Estrogens, A	Dexrazoxane may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
S Estrogens, B	Dexrazoxane may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Dexrazoxane.
Tadalafil	Dexrazoxane may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Tamsulosin	Dexrazoxane may decrease the excretion rate of Tamsulosin which could result in a higher serum level.

Teduglutide	Dexrazoxane may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Tegafur	Dexrazoxane may decrease the excretion rate of Tegafur which could result in a higher serum level.
Telavancin	Dexrazoxane may decrease the excretion rate of Telavancin which could result in a higher serum level.
Temazepam	Temazepam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Temozolomide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Temozolomide.
Temsirolimus	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Temsirolimus.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Dexrazoxane.
Teniposide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teniposide.
Tenofovir alafenamide	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dexrazoxane.
Tenofovir disoproxil	Tenofovir disoproxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Tenoxicam	Tenoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Teprotumumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teprotumumab.
Terbutaline	Dexrazoxane may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Teriflunomide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teriflunomide.
Testolactone	Dexrazoxane may decrease the excretion rate of Testolactone which could result in a higher serum level.
Testosterone	Dexrazoxane may decrease the excretion rate of Testosterone which could result in a higher serum level.
Testosterone	Dexrazoxane may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enan	Dexrazoxane may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone propi	Dexrazoxane may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
Testosterone	Dexrazoxane may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetracycline	Dexrazoxane may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Tetradecyl	Dexrazoxane may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Thalidomide	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thalidomide.
Thiabendazole	Dexrazoxane may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Thiethylperazine	Thiethylperazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Thiotepa	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thiotepa.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Ticagrelor	The risk or severity of bleeding can be increased when Ticagrelor is combined with Dexrazoxane.
borne encephalitis	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Dexrazoxane.
Ticlopidine	The risk or severity of bleeding can be increased when Ticlopidine is combined with Dexrazoxane.
Tiludronic acid	Dexrazoxane may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Timolol	Timolol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Tinidazole	Dexrazoxane may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Dexrazoxane.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Dexrazoxane.
Tiopronin	Dexrazoxane may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiotropium	Dexrazoxane may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Dexrazoxane.
Tixocortol	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tixocortol.
Tobramycin	Dexrazoxane may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tocilizumab.
Tocopherol	Dexrazoxane may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tofacitinib	Dexrazoxane may increase the immunosuppressive activities of Tofacitinib.
Tolazamide	Dexrazoxane may decrease the excretion rate of Tolazamide which could result in a higher serum level.
Tolbutamide	Dexrazoxane may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Tolcapone	Tolcapone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Tolfenamic acid	Tolfenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Tolmetin	Tolmetin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Tolterodine	Dexrazoxane may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Tolvaptan	Tolvaptan may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate	Topiramate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Topotecan	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Topotecan.
Torasemide	Torasemide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexrazoxane.
Trabectedin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trabectedin.
Tramadol	Tramadol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Trametinib	Dexrazoxane may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Dexrazoxane.
Trastuzumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trastuzumab emtansine.
Tretinoin	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tretinoin.
Triamcinolone	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Triamcinolone.
Triamterene	Triamterene may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	Dexrazoxane may decrease the excretion rate of Triazolam which could result in a higher serum level.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
Triethylenetetramine	Dexrazoxane may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Trifluridine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trifluridine.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Dexrazoxane.
Trilostane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trilostane.
Trimebutine	Dexrazoxane may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Trimethoprim	Dexrazoxane may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Trimetrexate	Dexrazoxane may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Tropisetron	Dexrazoxane may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dexrazoxane.
Typhoid Vaccine	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Dexrazoxane.
Typhoid Vi	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Dexrazoxane.
Upadacitinib	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Dexrazoxane.
Vaborbactam	Dexrazoxane may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Valentine	Dexrazoxane may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib	Valdecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Valganciclovir	Dexrazoxane may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Vancomycin	Dexrazoxane may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Varenicline	Dexrazoxane may decrease the excretion rate of Varenicline which could result in a higher serum level.
Varicella vaccine	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Dexrazoxane.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Dexrazoxane.
Vedolizumab	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vedolizumab.
Venlafaxine	Venlafaxine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Verapamil	Dexrazoxane may decrease the excretion rate of Verapamil which could result in a higher serum level.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dexrazoxane.
Vilanterol	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vilanterol.
Viloxazine	Dexrazoxane may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Vinblastine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vinblastine.
Vincristine	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vincristine.

Pregnancy and Lactation

FDA Pregnancy Risk Category: C

Pregnancy

The manufacturer makes no recommendation regarding use during pregnancy. This drug can cause fetal harm; if this drug is used during pregnancy, or the patient becomes pregnant, apprise them of the potential hazard to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose.

Lactation

No information is available on the use of dexrazoxane during breastfeeding. The manufacturer recommends that women not breastfeed during treatment and for 2 weeks following the final dose of dexrazoxane. However, because dexrazoxane is used with doxorubicin, the abstinence period might be longer, depending on the doxorubicin dose.

How should this medicine be used?

Dexrazoxane injection comes as a powder to be mixed with liquid and injected into a vein by a doctor or nurse in a hospital. When dexrazoxane injection is used to prevent heart damage caused by doxorubicin, it is given over 15 minutes just before each dose of doxorubicin. When dexrazoxane injection is used to prevent tissue damage after an anthracycline medication has leaked out of a vein, it is given over 1 to 2 hours once a day for 3 days. The first dose is given as soon as possible within the first 6 hours after the leak occurs, and the second and third doses are given about 24 and 48 hours after the first dose.

What special precautions should I follow?

Before receiving dexrazoxane injection,

tell your doctor and pharmacist if you are allergic to dexrazoxane, any other medications, or any ingredients in dexrazoxane injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention dimethylsulfoxide (DMSO) topical products.
tell your doctor if you have or have ever had heart, kidney, or liver disease.
tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant while you are receiving dexrazoxane injections. If you are receiving a dexrazoxane injection (Zinecard), you should use birth control during your treatment. If you are receiving dexrazoxane injection (Totect), you should use birth control during your treatment and for at least 6 months after your final dose. If you are male, you and your female partner should use birth control during your treatment and for 3 months after you stop receiving dexrazoxane injections (Protect). Talk to your doctor about birth control methods that will work for you. If you or your partner become pregnant while receiving dexrazoxane injection, call your doctor. Dexrazoxane may harm the fetus.
tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving dexrazoxane (Zinecard) injections. If you are receiving dexrazoxane injection (Totect), you should not breastfeed while you are receiving treatment and for 2 weeks after your final dose.
you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving dexrazoxane injections.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving a dexrazoxane injection.
you should know that treatment with dexrazoxane injection decreases but does not eliminate the risk that doxorubicin will damage your heart. Your doctor will still need to monitor you carefully to see how doxorubicin has affected your heart.

References

https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020212s013lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022025s015lbl.pdf
https://www.cancer.gov/about-cancer/treatment/drugs/dexrazoxanehydrochloride
https://pubchem.ncbi.nlm.nih.gov/compound/Dexrazoxane
https://pubchem.ncbi.nlm.nih.gov/compound/Dexrazoxane-hydrochloride
https://go.drugbank.com/drugs/DB00380
https://medlineplus.gov/druginfo/meds/a609010.html
https://en.wikipedia.org/wiki/Dexrazoxane
https://www.ncbi.nlm.nih.gov/books/NBK560559/
https://www.drugs.com/mtm/dexrazoxane.html
https://www.webmd.com/drugs/2/drug-11480/dexrazoxane-hcl-intravenous/details/list-contraindications
ChemIDplus

https://www.nlm.nih.gov/copyright.html

https://chem.nlm.nih.gov/chemidplus/sid/0024584096

https://chem.nlm.nih.gov/chemidplus/
DrugBank

https://www.drugbank.ca/legal/terms_of_use

Dexrazoxane

https://www.drugbank.ca/drugs/DB00380
DTP/NCI

https://www.cancer.gov/policies/copyright-reuse

Dexrazoxane

https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=169780
EPA DSSTox

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

Dexrazone

https://comptox.epa.gov/dashboard/DTXSID3040647

CompTox Chemicals Dashboard Chemical Lists

https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)

https://echa.europa.eu/web/guest/legal-notice

https://echa.europa.eu/information-on-chemicals

https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/168280
FDA Global Substance Registration System (GSRS)

https://www.fda.gov/about-fda/about-website/website-policies#linking

DEXRAZOXANE

https://gsrs.ncats.nih.gov/ginas/app/beta/substances/048L81261F
Hazardous Substances Data Bank (HSDB)

DEXRAZOXANE

https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7319
Human Metabolome Database (HMDB)

http://www.hmdb.ca/citing

Dexrazoxane

http://www.hmdb.ca/metabolites/HMDB0014524
ChEBI

(+)-dexrazoxane

http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50223

ChEBI Ontology

http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
FDA Pharm Classes

https://www.fda.gov/about-fda/about-website/website-policies#linking

DEXRAZOXANE

https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm

FDA Pharmacological Classification

https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
NCI Thesaurus (NCIt)

https://www.cancer.gov/policies/copyright-reuse

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1333

NCI Thesaurus Tree

https://ncit.nci.nih.gov
ChEMBL

http://www.ebi.ac.uk/Information/termsofuse.html

https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1738/

https://www.ebi.ac.uk/chembl/g/#browse/targets
Comparative Toxicogenomics Database (CTD)

http://ctdbase.org/about/legal.jsp

Dexrazoxane

https://ctdbase.org/detail.go?type=chem&acc=D064730
Drug Gene Interaction database (DGIdb)

http://www.dgidb.org/downloads

DEXRAZOXANE

https://www.dgidb.org/drugs/DEXRAZOXANE
Therapeutic Target Database (TTD)

Dexrazoxane

http://idrblab.net/ttd/data/drug/details/D07XVN
ClinicalTrials.gov

https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use

https://clinicaltrials.gov/
Drug Induced Liver Injury Rank (DILIrank) Dataset

https://www.fda.gov/about-fda/about-website/website-policies#linking

dexrazoxane

https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
European Medicines Agency (EMA)

https://www.ema.europa.eu/en/about-us/legal-notice

Savene (EMEA/H/C/000682)

https://www.ema.europa.eu/en/medicines/human/EPAR/savene
NCI Investigational Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

ADR-529

http://dtp.nci.nih.gov/NCI-InvestigationalDrugsCI92/169780%20(1992).txt
Drugs and Lactation Database (LactMed)

LICENSE

https://www.nlm.nih.gov/copyright.html

Dexrazoxane

https://www.ncbi.nlm.nih.gov/books/NBK500970/
EU Clinical Trials Register

https://www.clinicaltrialsregister.eu/
FDA Orange Book

https://www.fda.gov/about-fda/about-website/website-policies#linking

https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
WHO Anatomical Therapeutic Chemical (ATC) Classification

https://www.whocc.no/copyright_disclaimer/

https://www.whocc.no/atc/

ATC Code

https://www.whocc.no/atc_ddd_index/
National Drug Code (NDC) Directory

https://www.fda.gov/about-fda/about-website/website-policies#linking

DEXRAZOXANE

https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
NCI Cancer Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

Dexrazoxane Hydrochloride

https://www.cancer.gov/about-cancer/treatment/drugs/dexrazoxanehydrochloride
NLM RxNorm Terminology

https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html

dexrazoxane

https://rxnav.nlm.nih.gov/id/rxnorm/42736
Springer Nature

https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=19053893-732567483

https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=19053893-732550760
Thieme Chemistry

https://creativecommons.org/licenses/by-nc-nd/4.0/

https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=19053893-732567483
Wikidata

https://creativecommons.org/publicdomain/zero/1.0/

Dexrazoxane

https://www.wikidata.org/wiki/Q524995
Medical Subject Headings (MeSH)

https://www.nlm.nih.gov/copyright.html

Dexrazoxane

https://www.ncbi.nlm.nih.gov/mesh/68064730

MeSH Tree

http://www.nlm.nih.gov/mesh/meshhome.html

Topoisomerase II Inhibitors

https://www.ncbi.nlm.nih.gov/mesh/68059005

Antineoplastic Agents

https://www.ncbi.nlm.nih.gov/mesh/68000970

Cardiotonic Agents

https://www.ncbi.nlm.nih.gov/mesh/68002316
PubChem

https://pubchem.ncbi.nlm.nih.gov
KEGG

https://www.kegg.jp/kegg/legal.html

Therapeutic category of drugs in Japan

http://www.genome.jp/kegg-bin/get_htext?br08301.keg

USP drug classification

http://www.genome.jp/kegg-bin/get_htext?br08302.keg

Anatomical Therapeutic Chemical (ATC) classification

http://www.genome.jp/kegg-bin/get_htext?br08303.keg

Target-based classification of drugs

http://www.genome.jp/kegg-bin/get_htext?br08310.keg
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

GHS Classification Tree

http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
NORMAN Suspect List Exchange

LICENSE

Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0

https://creativecommons.org/licenses/by/4.0/

NORMAN Suspect List Exchange Classification

https://www.norman-network.com/nds/SLE/
PATENTSCOPE (WIPO)

SID 388674941

https://pubchem.ncbi.nlm.nih.gov/substance/388674941
NCBI

https://www.ncbi.nlm.nih.gov/projects/linkout

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician

Tests to discuss with doctor

Temperature chart and hydration assessment
CBC with platelet count if fever persists or dengue/other infection is possible
Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Internal learning pathway

Explore related RX articles

Related guides from RX Harun are grouped to help readers move from overview to symptoms, tests, treatment, and safe next steps.

Drugs (A - Z)

Vasodilator Drugs Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium…
Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine…
Methamphetamine – Uses, Dosage, Side Effects, Interactions Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.…
Vitamin D3 – Uses, Dosage, Side Effects, Interactions DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from…
Imidazole – Uses, Dosage, Side Effects, Interactions DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of…
Carbimazole Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is…

Read, save, and share this guide

Article Summary

Key Takeaways

RX Patient Tools

Mechanism of Action

Indications

Use in Cancer

Contraindications

Dosage?

Cardiomyopathy Prophylaxis

The dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g. 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin)

Extravasation

Side Effects

The Most Common

More common

Rare

Drug Interactions

Pregnancy and Lactation

Pregnancy

Lactation

How should this medicine be used?

What special precautions should I follow?

Before receiving dexrazoxane injection,

Related medical topics

Related Articles

Prepare before seeing a doctor

Which doctor may help?

What to tell the doctor

Questions to ask

Tests to discuss

Avoid these mistakes

Medicine safety and first-aid guide

Safe first steps

OTC medicine safety

Avoid these mistakes

Get urgent help if

Patient health record and symptom diary

Care roadmap for: Dexrazoxane Hydrochloride – Uses, Dosage, Side Effects, Interaction

Check danger signs first

Record the symptom story

Visit a qualified clinician

Do only useful tests

Follow up and return early if worse

Explore related RX articles

To Get Daily Health Newsletter

Dosage